This clinical trial is studying an investigational drug for people with obesity/overweight and weight-related conditions. We’re searching for adult men aged 18+ years, with a BMI of 27+ and who are ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Researchers identify a significant association between sugar-sweetened beverage tax and BMI changes among adults living in ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...